Mashup Score:5
OncLiveDr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer - 9 hours
Mashup Score:5
Twitter Feed: OncLive.com
Mashup Score:5
OncLiveBrain imaging should be considered for patients with advanced or metastatic renal cell carcinoma who have a high metastatic burden and who have progressed...
-
Brain imaging should be considered for patients w/ mRCC, as results from a multi-institutional cohort study found that 4.3% of 1689 patients w/ mRCC had incidental brain metastases without documented neurological symptoms @KotechaMD @sloan_kettering #kcsm https://t.co/3b65GRewfk https://t.co/3b65GRewfk - view on twitter
More coverage:
#kcsm
Mashup Score:5
OncLiveChallenges Arise as Public Health and Scientific Communication Enters Uncharted Territory - 6 hours
Mashup Score:5
It is difficult to dispute that these are troubling times for government officials and public health...
-
It is difficult to dispute that these are troubling times for government officials and public health agencies. @DrMaurieMarkman @CancerCenter #COVID19 https://t.co/JhmU06H9kZ - view on twitter
More coverage:
#covid19
Mashup Score:4
OncLivePredicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC - 18 hours
Mashup Score:4
Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung...
-
Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC @CedarsSinai @gotoPER #ILCC2021 #lcsm https://t.co/4J29C5JJil - view on twitter
Mashup Score:4
OncLiveWith Novel Combos on the Horizon, End Points Beyond OS May Hold Promise in HR-MDS - 16 hours
Mashup Score:4
Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can...
-
Novel combinations w/ agents, such as pevonedistat or magrolimab, plus hypomethylating agents are being evaluated to see if they can improve on theMS for patients w/ higher-risk myelodysplastic syndrome @MikkaelSekeres @SylvesterCancer @UMiamiHealth #MDS https://t.co/ZUQWHBIRng - view on twitter
More coverage:
#mds
Mashup Score:3
OncLiveAnti-EGFR/Chemo Combos Allow for Tailored Approach in mCRC - 11 hours
Mashup Score:3
Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing...
-
Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing indications @ardamanshergill @UChicagoMed #crcsm https://t.co/8ggcCfTLKy - view on twitter
More coverage:
#crcsm
Mashup Score:3
OncLiveNew Strategies for RET Inhibition May Expand Their Role in NSCLC - 1 day
Mashup Score:3
RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET...
-
New Strategies for RET Inhibition May Expand Their Role in NSCLC @ReckampK @CedarsSinai @gotoPER #ILCC2021 #lcsm https://t.co/rrhmtRciXM - view on twitter
Mashup Score:3
OncLiveLeslie L. Montgomery, MD, and Tara M. Balija, MD, discuss the benefits of a novel reflector device in patients with breast cancer, its efficacy...
-
Patients w/ breast cancer whose disease has spread to the axillary lymph nodes, the use of reflector device technology can help to accurately pinpoint cancerous nodes for resection @HackensackUMC @BCRJournal @JTCancerCenter @HMHNewJersey @SetonHall #bcsm https://t.co/ZTiU7LZaD8 https://t.co/ZTiU7LZaD8 - view on twitter
More coverage:
#bcsm
Mashup Score:2
OncLiveOptimizing Osimertinib Treatment Strategies Relies on Identification of Resistance - 1 day
Mashup Score:2
Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the...
-
Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance @UCD_Cancer @gotoPER #ILCC2021 #lcsm https://t.co/qD2maDIyjo - view on twitter
Mashup Score:2
OncLiveRoche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe - 18 hours
Mashup Score:2
Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab to the treatment of patients with early or locally advanced triple-negative...
-
Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab to the treatment of patients with early or locally advanced triple-negative breast cancer in Europe. @myESMO #bcsm https://t.co/X3lQFB6VQq - view on twitter
More coverage:
#bcsm
Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast...
WATCH: @stolaney1, of @DanaFarber, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer. #bcsm https://t.co/MngcTkWllS - view on twitter